CLINICAL EVALUATION OF NEGGRAM, A NEW CHEMOTHERAPEUTIC AGENT.
D003556:Cystitis; D004358:Drug Therapy; D004361:Drug Tolerance; D004823:Epididymitis; D004927:Escherichia coli Infections; D006801:Humans; D007239:Infections; D007669:Kidney Calculi; D007709:Klebsiella; D008297:Male; D009287:Naphthyridines; D009325:Nausea; D011512:Proteus Infections; D011704:Pyelonephritis; D013203:Staphylococcal Infections; D013290:Streptococcal Infections; D013943:Thymol; D014116:Toxicology; D014525:Urethral Stricture; D014526:Urethritis; D014552:Urinary Tract Infections; D014581:Urticaria; D014717:Vertigo
D009287:Naphthyridines; D013943:Thymol
CYSTITIS; DRUG THERAPY; DRUG TOLERANCE; EPIDIDYMITIS; ESCHERICHIA COLI INFECTIONS; INFECTION; KIDNEY CALCULI; KLEBSIELLA; NAPHTHYRIDINES; NAUSEA; PROTEUS INFECTIONS; PYELONEPHRITIS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; THYMOL; TOXICOLOGIC REPORT; URETHRAL STRICTURE; URETHRITIS; URINARY TRACT INFECTIONS; URTICARIA; VERTIGO